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Abstract: 
 
Objective: The aim of the study was to assess the total protein, lysozyme, and immunoglobulin 
A (IgA) content of unfortified and fortified Holder-pasteurized donor human milk (HPDHM) 
during 96 hours of refrigerated storage. Study Design: HPDHM was prepared in a hospital 
feeding room and subjected to treatment with 3 different fortifiers: an acidic, bovine-based (F-
ACID), a neutral, bovine-based, and a human milk–derived (F-HUM) fortifier. Unfortified 
HPDHM served as the control (CONTROL). Samples were stored at 4°C, and every 24 hours, a 
1-mL aliquot was removed for analysis. Results: At baseline, there was a significant difference 
in protein (mean, standard deviation) concentration (g/dL) between control (1.3, 0.1) and all 
other treatments (F-ACID = 2.0, 0.2; neutral, bovine-derived fortifier = 2.2, 0.1; F-HUM = 2.5, 
0.1; P < 0.001). Lysozyme and IgA were significantly lower in the F-ACID group (P < 0.001). 
Lysozyme and IgA were significantly higher in the F-HUM group (P < 0.001). There was no 
significant effect of storage time (P > 0.9) for all dependent variables. Conclusion: The type of 
fortifier has a more significant impact on bioactive components in fortified HPDHM than 
does storage time. Our findings of lack of negative impact of refrigeration storage time on the 
protein and bioactive components of donor milk strengthen the recent recommendations to 
extend storage time to 48 hours. 
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Article: 
 
 
 
What Is Known 
• Unfortified Holder-pasteurized donor human milk retains lysozyme and immunoglobulin A activity for 
up to 7 days of refrigerated storage. 
• Neonatal intensive care units in the United States routinely fortify human milk for very-low-birth-weight 
infants. 
 
What Is New 
• Acidic fortifiers significantly lower the lysozyme and immunoglobulin A activity in Holder-
pasteurized donor human milk. 
• Human milk–derived fortifiers significantly increase the lysozyme and immunoglobulin A activity of 
Holder-pasteurized donor human milk. 
• Refrigerated storage for up to 96 hours had no impact on the total protein, lysozyme activity, and 
immunoglobulin A activity in fortified Holder-pasteurized donor human milk. 
 
The use of pasteurized donor human milk is supported by the World Health Organization, the 
American Academy of Pediatrics, and the United States Surgeon General as an important 
strategy for improving health outcomes in premature infants when their mother's milk is not 
available (1–3). In the United States, donor milk use is on the rise, with more than 65% of neonatal 
intensive care units (NICUs) reporting use in 2015 (4–6). To ensure the safety of donor milk, the 
Human Milk Banking Association of North America (HMBANA) and other international milk 
bank networks have issued guidelines, including appropriate storage temperatures and durations. 
Current best practices for the refrigerated storage of Holder-pasteurized donor human milk 
(HPDHM) state that thawed milk should be stored in the refrigerator and used within 48 hours(7). 
 
Evidence is emerging that unfortified HPDHM remains free of microbial growth during 
refrigerated storage over 4 days, suggesting an opportunity to extend the expiration date and 
reduce unnecessary waste of a costly and valuable resource (8–12). Affordability was the most 
frequently cited barrier of nonuse in a 2013 survey of 183 level 3 NICUs (5). Research to evaluate 
the feasibility of extending defrosted HPDHM expiration dates has the potential to reduce cost 
barriers associated with a short shelf life and product waste. 
 
Although bacteria levels of HPDHM are one marker of product quality and safety, additional 
research is needed regarding the retention of nutrients and immune factors in HPDHM during 
extended refrigerated storage to inform evidence-based guidelines on appropriate clinical use. In 
addition, it is now common practice in the NICU to fortify mother's milk and HPDHM with 
human milk fortifiers (HMF) to increase protein and energy content (4). The effects of 
refrigerated storage time on the retention of macronutrients and other bioactive components 
in fortified HPDHM remain largely unstudied (13). The objective of this study is to assess total 
protein, lysozyme, and immunoglobulin A (IgA) in unfortified and fortified HPDHM during 96 
hours of refrigerated storage. Lysozyme and IgA were selected for this study because of their 
antimicrobial properties (14) and their partial retention after pasteurization (15). A 96-hour window 
was selected as the maximum amount of time a hospital might take to use a standard 4 oz bottle 
of HPDHM when starting preterm infants at a low feeding volume (15–20 mL · kg−1 · day−1) and 
advancing at 10 to 20 mL · kg−1 · day−1(16). 
 
METHODS 
 
HPDHM was acquired through an HMBANA milk bank (The New York Milk Bank, Valhalla, 
NY). Twelve unique batches were subject to 4 treatments: unfortified HPDHM (CONTROL) 
served as the control; fortification to 24 kcal/oz with a liquid, acidic, bovine milk–based whey 
hydrolysate fortifier (F-ACID) (Enfamil Human Milk Fortifier Acidified Liquid, Mead Johnson, 
Chicago, IL); fortification to 24 kcal/oz with a liquid, neutral, bovine milk–based fortifier (F-
NEUT) (Similac Human Milk Fortifier Concentrated Liquid, Abbot, Chicago, IL); and 
fortification to 28 kcal/oz with a liquid, neutral, human milk–based fortifier (F-HUM) 
(Prolact+8, Prolacta Bioscience, City of Industry, CA). 
 
Sample Preparation 
 
Fortification and handling of the milk samples occurred in the hospital milk preparation room at 
Westchester Medical Center (Valhalla, NY) between September 2016 and December 2016 by a 
trained Milk Technician. Each unique batch of HPDHM was mixed according to the protocol 
outlined here: F-ACID was fortified with 1 vial (5 mL) of Enfamil HMF added to 25 mL 
HPDHM to reach 24 kcal/oz; F-NEUT with 1 envelope (5 mL) of Similac HMF fortifier plus 25 
mL HPDHM to reach 24 kcal/oz; and F-HUM with Prolact+8 HMF (40 mL) plus 60 mL 
HPDHM, to reach 28 kcal/oz. Once mixed, all samples were stored in clean containers labeled 
with the HPDHM batch number and a unique letter code corresponding to fortification type. 
With the exception of the milk technician, all researchers were blinded to treatment type until 
after all samples were analyzed and all data were collected. 
 
A 5 mL aliquot from each control and fortification group was stored in the refrigerator in a clean, 
glass container. Time 0 for the fortified samples began once the samples had been fortified and 
placed in the refrigerator. Time 0 for the CONTROL began once the unfortified HPHDM was 
aliquoted in the glass container and refrigerated. Samples were stored in the refrigerator 
throughout the study and a daily log of refrigerator temperatures was kept. Every 24 hours, each 
5 mL aliquot was opened, and 1 mL of milk was removed using a sterilized pipette and 
transferred to a clean, glass bottle. The samples were resealed and returned to the refrigerator. 
The 1 mL aliquot was labeled with the storage time (0, 24, 48, 72, 96 hours) and immediately 
stored at −20°C in a specimen bag that contained the batch number and a unique letter code that 
identified the treatment group. When the 96-hour sample was added to the specimen bag, the bag 
was labeled with the date on which the last sample was collected. When all 12 batches had been 
processed, they were packaged on dry ice and shipped from Westchester Medical Center to the 
Nutrition Department at the University of North Carolina Greensboro (Greensboro, NC) for 
analysis. One batch was missing the F-NEUT treatment; therefore, the study generated 235 total 
samples for analysis, with a total of 60 samples across 5 time points for the unfortified, F-ACID, 
and F-HUM treatments, and 55 samples across 5 time points for the F-NEUT treatment. 
 
In the laboratory, samples were thawed at room temperature and with the help of body heat, 
being held in the hands and pockets of the lab technician, mixed using a vortexer for 
approximately 3 seconds, divided into 125 μL aliquots, and then immediately refrozen at −20°C 
until analysis. Samples were stored frozen for between 4 and 15 months, and similar thawing 
techniques were employed before sample analysis. 
 
Sample Analysis 
 
For each sample collected, IgA activity, lysozyme activity, and total protein content were 
assessed. IgA activity was measured by enzyme-linked immunosorbent assay, which has 
previously been described in detail (17,18). Escherichia coli acquired from the STEC Center 
(Michigan State University, East Lansing, MI) were used to prepare an antigen for coating the 
wells of a microplate. IgA antibodies from human milk bind to the E coli antigens and also bind 
with anti-human-IgA antibody labeled with horseradish peroxidase (part number A0295, Sigma 
Aldrich, St Louis, MO). 2,2′-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (part number 
A1888, Sigma Aldrich) was used as a colorimetric substrate. Absorbance was measured at 405 
nm via spectrophotometry (Synergy HT, BioTek Instruments, Winooski, VT) and IgA activity 
was computed based on a known human colostrum IgA standard (part number I2636, Sigma 
Aldrich). 
 
Lysozyme activity was analyzed by changes in turbidity to a microbial suspension 
of Micrococcus lysodeikticus (part number NC9310237, Fisher Scientific, Hampton, NH) at 450 
nm over the course of 7 minutes, measured by spectrophotometry (Synergy HT, Bio-Tek 
Instruments) (19,20). 
 
Total protein was measured by the bicinchoninic acid (BCA) method (part number PI23225, 
Fisher Scientific) (21). This assay measures the reduction of Cu+2 by the acidic side chains of 
human milk proteins and the resulting color change, induced by BCA, which exhibits a strong 
absorbance at 562 nm. Samples were diluted 1:20 with deionized water and analyzed via 
spectrophotometry (Synergy HT, Bio-Tek Instruments) alongside known bovine serum albumin 
standards. 
 
For each control sample, all corresponding fortified samples and all time points (4 treatments × 5 
time points = 20 samples total) were measured on the same 96-well plate to eliminate interassay 
variability. 
 
Statistical Analysis 
 
Statistical analysis was performed using SAS software 9.4 Enterprise Edition (SAS Institute, Inc, 
Cary, NC). Descriptive statistics were computed for the main effects of treatment and time. 
Repeated measures were assessed using the mixed procedure to determine the effects of 
treatment, time, and an interaction between treatment and time. Main effects that were 
statistically different were evaluated using an analysis of variance with a Tukey adjustment for 
multiple comparisons. P values were set at 0.05. This study was classified as exempt by the 
institutional review board at the University of North Carolina Greensboro (protocol 16-0411). 
 
RESULTS 
 
Each analytical test was performed in triplicate and the resulting average coefficients of variation 
for assays were as follows: total protein, 2.9%; lysozyme activity, 9.4%; and IgA activity, 2.3%. 
For IgA activity, all R2 values were >0.996, and for lysozyme, all R2 values were >0.979. The F-
NEUT treatment group was missing in sample 1; therefore, analysis was performed with the 
incomplete dataset of 12 samples, and with a complete dataset of 11 samples. None of the 
significant conclusions changed; therefore, all data presented represent analysis using the 11 
samples in which all treatments and time points were available. 
 
Effect of Fortification at Baseline (Time 0) 
 
Using the repeated measures analysis, there was a highly significant impact of treatment (P < 
0.001) for all dependent variables. Descriptive statistics by treatment at baseline (time 0) are 
summarized in Table 1. 
 
Table 1. Descriptive statistics by treatment at baseline (time = 0) 
 Control F-ACID F-NEUT F-HUM 
Samples 11 11 11 11 
Protein, g/dL 1.2 (0.1)* 2.0 (0.2)† 2.2 (0.1)† 2.5 (0.1)‡ 
Lysozyme, units/mL 5270 (890)* 3340 (1660)† 4530 (1150)‡ 6230 (500)§ 
IgA, mg/dL 80.3 (22.4)* 70.0 (12.3)† 89.5 (18.1)* 144.4 (16.1) ‡ 
Data represent means and standard deviations. Differences between groups were assessed by analysis of variance 
(ANOVA) analysis with a Tukey test for multiple comparisons. Entries in the same row with different superscripts 
are statistically different (P<0.05). 
F-ACID = acidic bovine–derived fortifier; F-HUM = human milk–derived fortifier; F-NEUT = neutral bovine–
derived fortifier; IgA = immunoglobulin A; UNFORT = unfortified. 
 
All 3 fortifiers significantly increased the total protein concentration of HPDHM (F-ACID 2.0 
g/dL, F-NEUT 2.2 g/dL, F-HUM 2.5 g/dL, P < 0.05) compared to control (1.2 g/dL). Total 
protein was not significantly different between F-ACID and F-NEUT treatments (P = 0.15). As 
expected F-HUM treatment group had a significantly higher protein concentration compared 
with all other treatments (P < 0.0001). 
 
Lysozyme activity was significantly different in all treatment groups (P < 0.001). Fortification 
with F-ACID resulted in a significant decrease in lysozyme activity compared to all other 
treatments (P < 0.001), with a 37% reduction compared to control. Lysozyme was undetectable 
at all time points in the F-ACID treatment group of sample 5. Mean lysozyme activity was 
significantly higher in F-HUM group compared with all other treatments (P < 0.001), with an 
18% increase compared to control. 
 
IgA activity was not significantly different between F-NEUT and control samples (P = 0.23). 
There was significant decrease in mean IgA activity with F-ACID treatment (P < 0.001) 
compared to all other treatments, with a 13% reduction compared to control. There was a 
significantly increase in mean IgA activity in F-HUM treatment group (P < 0.001) compared to 
the other treatments, with an 80% increase compared to control. Box and whisker plots of the 
baseline data (time 0) are presented in Figure 1. 
 
 
 
 
Figure 1. Holder-pasteurized donor human milk (n = 11 per treatment) at baseline (time 0) based 
on fortification status. Distributions with the same letter are not statistically different (P > 0.05) 
using an analysis of variance (ANOVA) analysis with a Tukey test for multiple comparisons. In 
the box and whisker plots, the box spans the interquartile range, the line represents the median, 
the diamond represents the mean, and the top and bottom lines extend to the highest and lowest 
observations. 
 
Effect of Refrigerated Storage Time 
 
Neither unfortified nor fortified HPDHM samples showed any significant changes over 96 hours 
of refrigeration. Time had no significant impact on protein concentration or the activity of 
lysozyme or IgA in any of the samples (P > 0.97 for all variables). Furthermore, there was no 
significant interaction between fortification type and storage time (P > 0.05 for all variables). 
Descriptive statistics for the study time points are summarized in Table 2. 
 
Table 2. Descriptive statistics for all treatments by time 
 Protein, g/dL Lysozyme, units/mL IgA, mg/dL 
Hour 0 2.0 (0.5) 4840 (1520) 96.0 (33.7) 
Hour 24 1.9 (0.5) 4920 (1570) 97.3 (33.4) 
Hour 48 2.0 (0.5) 4820 (1490) 97.6 (35.1) 
Hour 72 1.9 (0.5) 4830 (1560) 97.8 (36.0) 
Hour 96 1.9 (0.5) 4930 (1700) 97.8 (36.3) 
Data represent means and standard deviations (n¼44 samples per time point). There were no statistically 
significant differences between groups (P>0.05). 
IgA = immunoglobulin A. 
 
DISCUSSION 
 
There is limited information regarding the effects of refrigerated storage on fortified HPDHM(13). 
In this study, 96 hours of refrigerated storage had no significant impact on the total protein 
concentration and the activity of lysozyme and IgA in unfortified and fortified HPDHM. Studies 
of refrigerated storage of unfortified HPDHM support our findings. Meng et al (10) reported no 
significant change in total protein, lysozyme activity, or IgA activity in unfortified HPDHM that 
was stored for up to 7 days in the refrigerator. Silvester et al (22) studied the bactericidal capacity 
of unfortified HPDHM against E coli for 72 hours of refrigerated storage and found no 
significant changes. 
 
Regarding differences among treatments at baseline, fortification with commercial HMF resulted 
in a 62% to 103% increase in protein concentration compared to control. Although this result is 
unsurprising, it is important to acknowledge that these products indeed do what they claim to do, 
which is to boost the protein content of human milk. Other studies have described similar 
increases. Donovan et al (23) reported significant, although somewhat greater, increases in protein 
concentrations of both MOM and HPDHM fortified with F-NEUT and F-ACID HMF compared 
to unfortified. 
 
Similarly, as it was the only human milk–based HMF included in the study and the only 
treatment innately containing lysozyme and IgA, it is no surprise that only F-HUM treatment 
affected significant increases in both lysozyme and IgA activity in HPDHM. IgA in human milk 
has been associated with reduced illness in breast-feeding infants (24). Similarly, in models of 
neonatal malnutrition using a piglet, dietary human lysozyme was associated with improved gut 
barrier function (25). Increasing the antimicrobial proteins in HPDHM for the preterm infant may 
have clinical benefits and warrants further investigation. Fortification with F-HUM also resulted 
in a significantly higher protein concentration compared to the other fortifiers. This is very likely 
due to the fact that these samples were mixed to 28 kcal/oz due to clinical need at the time of 
sample collection, compared to the other treatments, which were mixed to 24 kcal/oz. 
 
At baseline, HPDHM fortified with F-ACID exhibited significant declines in both lysozyme and 
IgA activity compared to all other treatments. Anytime acidity is increased, the risk for 
deactivating and denaturing proteins increases. It is quite likely that this is the case here. 
Although the pH of the HPDHM in this study was not measured due to small sample volume, 
Donovan et al (23) found that fortification with an acidic HMF resulted in a pH of 4.96 in preterm 
HPDHM and a pH of 5.10 in term HPDHM. Quan et al (26) reported a 19% reduction in the 
lysozyme activity, and no change in IgA, in raw human milk fortified with a human milk fortifier 
that was available in the early 1990s, although no additional information on the fortifier 
characteristics were provided. Reduction of the bioactive factors in HPDHM through the use of 
acidic fortifiers may have immune consequences for the vulnerable preterm neonate. Emerging 
evidence also suggests acidic fortifiers lead to higher rates of feeding intolerance and metabolic 
acidosis in the preterm infant (27). 
 
Study Limitations 
 
In order to aliquot and complete analyses in the laboratory, the HPDHM samples underwent 4 
freeze-thaw cycles, which is 2 more than traditionally encountered in normal use (12,28). Each 
freeze/thaw cycle brings with it the risk of destabilized casein micelles and the altered quaternary 
structure of whey proteins, which can result in the formation of precipitates (29). In our study, the 
F-ACID treatment resulted in precipitates in the samples which required additional handling 
steps so as not to interfere with spectrophotometry readings. These samples were thawed in a 
shaking water bath at 35°C and 80 rpm for 60 minutes to improve homogenization. It is possible 
that the multiple freeze-thaw cycles contributed to this phenomenon. That being said, all samples 
were subject to the same number of freeze-thaw cycles, which allows for comparison across the 
study. In the hospital feeding room, the F-HUM was mixed to 28 kcal/oz, although both the F-
ACID and F-NEUT were mixed to 24 kcal/oz. The human milk–based fortifier used in this study 
was a higher calorie and protein fortification than originally planned due to clinical needs in the 
hospital during the study period, and it would be expected to provide more protein than the 
bovine milk–based fortifiers. This explains the average higher protein concentrations measured 
in this treatment group compared to the others. However, it is also likely that, had the human 
milk–based HMF been mixed to 24 kcal/oz like the F-ACID and F-NEUT HMF, the levels of 
lysozyme and IgA activity would still have been significantly higher than all other treatments, 
due to the fact that only F-HUM would likely contain meaningful quantities of these 
antimicrobial proteins. The BCA assay over-reports actual protein content; however, it has been 
validated as reliable for measuring human milk (R2 > 0.99) and is therefore appropriate for 
assessing differences between groups (21). We did not evaluate bacterial growth in our study, 
which is an important consideration in the NICU setting. 
 
Gaps in Literature and Future Research Implications 
 
Very few studies have specifically evaluated the impact of long-term refrigerated or frozen 
storage of HPDHM. Many address long-term storage in combination with other pasteurization 
methods, treatments, and outcomes, which can make the results specific to storage difficult to 
assess. In addition, small sample size and the use of milk samples from a single donor rather than 
samples of pooled HPDHM are common limitations. In order to more accurately represent 
HPDHM found in the NICU, future studies should use pooled milk samples in clinically relevant 
volumes and be designed to emulate clinical practices, with the opening and closing of 
refrigerators and containers. More research is also needed into how fortifiers impact essential 
micronutrients in HPDHM. 
 
CONCLUSIONS 
 
As expected, fortification with liquid bovine and human milk–based fortifies significantly 
increases the protein concentration in donor human milk. Human milk–based fortifier provides 
additional IgA and lysozyme which may be beneficial. Our findings of lack of negative impact of 
refrigeration storage time on the protein and bioactive components of donor milk strengthen the 
recent HMBANA recommendation to extend storage time to 48 hours. The observed decline in 
IgA and lysozyme with acidic fortification is concerning and warrants further studies. 
 
REFERENCES 
 
1. AAP SECTION ON BREASTFEEDING. Breastfeeding and the use of human 
milk. Pediatrics 2012; 129:e827–e841. 
2. Lowe NK. The surgeon general's call to action to support breastfeeding. J Obstet Gynecol 
Neonatal Nurs 2011; 40:387–389. 
3. WHO. Infant and Young Child Nutrition: Biennial Progress Report. World Health Assembly 
61.20. Geneva, Switzerland: World Health Organization; 2008. 
4. Perrin MT. Donor human milk and fortifier use in United States level 2, 3, and 4 neonatal 
care hospitals. J Pediatr Gastroenterol Nutr 2018; 66:664–669. 
5. Parker MGK, Barrero-Castillero A, Corwin BK, et al. Pasteurized human donor milk use 
among US level 3 neonatal intensive care units. J Hum Lact 2013; 29:381–389. 
6. Perrine CG, Scanlon KS. Prevalence of use of human milk in US advanced care neonatal 
units. Pediatrics 2013; 131:1066–1071. 
7. The Human Milk Banking Association of North America. Best Practice for Expressing, 
Storing and Handling Human Milk in Hospitals, Homes, and Child Care Settings. 4th edFort 
Worth, TX: Human Milk Banking Association of North America; 2019. 
8. Cohen RS, Huang C-FR, Xiong SC, et al. Cultures of Holder-pasteurized donor human 
milk after use in a neonatal intensive care unit. Breastfeed Med 2012; 7:282–284. 
9. Vickers AM, Starks-Solis S, Hill DR, et al. Pasteurized donor human milk maintains 
microbiological purity for 4 days at 4°C. J Hum Lact 2015; 31:401–405. 
10. Meng T, Perrin MT, Allen JC, et al. Storage of unfed and leftover pasteurized human 
milk. Breastfeed Med 2016; 11:538–543. 
11. Taylor E, Labbok M. Donor human milk access and use in the United States: Findings and 
recommendations. Carolina Global Breastfeeding Institute. 
2014. http://breastfeeding.sph.unc.edu/files/2014/11/DHM_I_Report_May-15-cost-
truncated.pdf. Accessed on January 12, 2018. 
12. Spatz DL, Robinson AC, Froh EB. Cost and use of pasteurized donor human milk at a 
children's hospital. J Obstet Gynecol Neonatal Nurs 2018; 47:583–588. 
13. Schlotterer HR, Perrin MT. The effects of refrigerated and frozen storage on holder-
pasteurized donor human milk: a systematic review. Breastfeed Med 2018; 13:465–472. 
14. Lönnerdal B. Bioactive proteins in human milk: health, nutrition, and implications for infant 
formulas. J Pediatr 2016; 173:S4–S9. 
15. Peila C, Moro G, Bertino E, et al. The effect of holder pasteurization on nutrients and 
biologically-active components in donor human milk: a review. Nutrients 2016; 8:477–496. 
16. Fernandes CJ, Pammi M, Katakam K. Guidelines for Acute Care of the Neonate. Section of 
Neonatology, Department of Pediatrics, Baylor College of Medicine, 25th edHouston, TX: 
2017. 
17. Chen HY, Allen JC. Human milk antibacterial factors: the effect of temperature on defense 
systems. Adv Exp Med Biol 2001; 501:341–348. 
18. Viazis S, Farkas B, Allen J. Effects of high pressure processing on immunoglobulin A and 
lysozyme activity in human milk. J Hum Lact 2007; 23:253–261. 
19. Shugar D. The measurement of lysozyme activity and the ultra-violet inactivation of 
lysozyme. Biochim Biophys Acta 1952; 8:302–309. 
20. Lee YC, Yang D. Determination of lysozyme activities in a microplate format. Anal 
Biochem 2002; 310:223–224. 
21. Keller RP, Neville MC. Determination of total protein in human milk: comparison of 
methods. Clin Chem 1986; 32:120–123. 
22. Silvester D, Ruiz P, Martinez-Costa C, et al. Effect of pasteurization on the bactericidal 
capacity of human milk. J Hum Lact 2008; 24:371–376. 
23. Donovan R, Kelly SG, Prazad P, et al. The effects of human milk fortification on nutrients 
and milk properties. J Perinatol 2017; 37:42–48. 
24. Breakey AA, Hinde K, Valeggia CR, et al. Illness in breastfeeding infants relates to 
concentration of lactoferrin and secretory immunoglobulin A in mother's milk. Evol Med 
Public Health 2015; 2015:21–31. 
25. Garas LC, Hamilton MK, Dawson MW, et al. Lysozyme-rich milk mitigates effects of 
malnutrition in a pig model of malnutrition and infection. Br J Nutr 2018; 120:1131–1148. 
26. Quan R, Yang C, Rubinstein S, et al. The effect of nutritional additives on anti-infective 
factors in human milk. Clin Pediatr (Phila) 1994; 33:325–328. 
27. Schanler RJ, Groh-Wargo SL, Barrett-Reis B, et al. Improved outcomes in preterm infants 
fed a nonacidified liquid human milk fortifier: a prospective randomized clinical trial. J 
Pediatr 2018; 202:31.e2–37.e2. 
28. Section VI. Milk bank procedures. In: Guidelines for the Establishment and Operation of 
a Donor Human Milk Bank. FortWorth, TX: The Human Milk Banking Association of North 
America; 2018:34–45. 
29. García-Lara NR, Escuder-Vieco D, García-Algar O, et al. Effect of freezing time on 
macronutrients and energy content of breastmilk. Breastfeed Med 2012; 7:295–301. 
